We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

XELB:NASDAQXcel Brands, Inc Analysis

Data as of 2026-05-11 - not real-time

$2.29

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Xcel Brands, Inc. (XELB) is trading at $2.29, comfortably above its 20‑day SMA of $2.15 and the 50‑day SMA of $1.75, indicating a short‑term bullish bias. The RSI of 59 and a bullish MACD histogram (+0.0036) further support momentum, while the Fear & Greed Index shows "Extreme Greed," suggesting strong market appetite. Fundamentally, the company is under severe pressure: revenue has fallen 3‑4% YoY to $4.94 M, gross margin is reported at 100% (likely a data anomaly), and operating margins are deeply negative at –167%, with a trailing EPS of –$5.08. The balance sheet is strained, featuring a debt‑to‑equity ratio of 114%, total debt of $18.1 M versus cash of $1.15 M, and a max drawdown of –73%. Volatility is extreme at over 112% on a 30‑day basis and beta near 2, amplifying price swings. Despite these challenges, the upside/downside potential is estimated at +118%, and the price‑to‑book ratio of 0.59 hints at a potentially undervalued equity. The volume trend is decreasing, raising concerns about liquidity, while the company has no dividend history, making income generation unlikely. In summary, technicals are favorable but the fundamentals are weak, creating a high‑risk, high‑reward profile.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Bullish technical indicators (price above SMA20, bullish MACD)
  • Extreme market optimism (Fear & Greed Index)
  • Weak earnings and high debt increase downside risk

Medium Term

1–3 years
Positive
Model confidence: 6/10

Key Factors

  • Significant upside potential (+118% upside/downside)
  • Undervalued price relative to book value
  • Potential upside if cost‑structure improvements materialize

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Turnaround opportunity through strategic brand licensing and live‑stream commerce
  • Long‑term valuation appeal given low price‑to‑book
  • Risk mitigation if debt is reduced and cash flow improves

Key Metrics & Analysis

Financial Health

Revenue Growth-3.40%
P/E Ratio-1.1
ROE-79.47%
ROA-9.74%
Debt/Equity114.20
P/B Ratio0.6
Op. Cash Flow$-7023000
Free Cash Flow$-6971875

Technical Analysis

TrendBullish
RSI59.6
Support$1.28
Resistance$2.47
MA 20$2.15
MA 50$1.75
MA 200$1.48
MACDBullish
VolumeDecreasing
Fear & Greed Index90.73

Valuation

Target Price$5.00
Upside/Downside118.35%
GradeUndervalued
TypeValue

Risk Assessment

Beta1.95
Volatility112.39%
Sector RiskHigh
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.